On Thursday (July 25), England-based tobacco company Imperial Brands (LSE:IMB,OTCQX:IMBBF) added to its marijuana exposure thanks to a new C$123 million investment in Auxly Cannabis Group (TSXV:XLY,OTCQX:CBWTF).
Imperial will obtain a 19.9 percent stake in the company since the deal is structured as debenture. The price per share was set at C$0.81 for the transaction, which represents an 11 percent premium for Auxly’s closing price on Wednesday (July 24).
“Auxly’s unique assets and capabilities, including strong science and product development credentials, make it an ideal partner for Imperial in the legal Canadian cannabis market,” Matthew Phillips, Imperial’s chief development officer, said in a press release.
— Imperial Brands PLC (@ImperialBrands) July 25, 2019
The transaction will be set in a three year term with a fixed annual interest rate of 4 percent. With this investment, Imperial also secured itself one of the five director seats in the Auxly board.
Auxly operates as a cannabis investment firm looking for partnerships in the space to add to its portfolio. The company is an active investment participant in nine cannabis cultivation operations in Canada.
Shares of the Canadian cannabis company rocketed over 20 percent in value following confirmation of the investment deal at the opening bell. Auxly shares closed at a price of C$0.91 on Thursday, representing a boost of 24.66 percent in value.
Chuck Rifici, chairman and CEO of Auxly, said in a press release that his company had been selected after Imperial completed an evaluation of the Canadian cannabis market.
As part of the deal, Auxly will gain immediate access to licenses for Imperial’s lineup of vape technology through subsidiary Nerudia.
According to Auxly, the cannabis firm will gain exclusivity with Imperial as the only partner for the entire development cycle for all types of cannabis products across the world.
“We are particularly excited to partner with Imperial Brands on current and future intellectual property and product development,” Rifici said.
Nerudia is a vaporizer developer working on the design and production of next generation vaping products.
Cannabis edibles and extracts are set to become legal in Canada starting on October 17. Health Canada, the regulatory body overseeing the marijuana industry, estimates these products will hit the market for sale sometime in mid-December.
In response to the collaboration for vaporizer technology, Imperial further explained: “The shared ability to rapidly innovate as the Canadian market evolves is key to future growth and Auxly will work closely with a small dedicated team from Nerudia in developing a portfolio of new and enhanced brands and products.”
This deal isn’t the first time Imperial has invested in the marijuana industry in some capacity. In June 2018, Imperial gained a stake in British biotech research company Oxford Cannabinoid Technologies.
Before the investment announcement was made, Auxly’s shares slumped throughout 2019, dropping 23.96 percent in value.
Similarly, the British tobacco company hasn’t fared all too well in the trading market, taking in a decline of 10.35 percent in 2019 as of Wednesday’s close.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure: Inner Spirit Holdings is a client of the Investing News Network. This article is not paid-for content.
American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.
Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.
Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.
As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.
A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.
BioHarvest Sciences Inc. Unveils the Unique Polyphenolic Content of Its Upcoming Olive-Based Nutraceutical
The product will include polyphenols known to have significant health benefits.
BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.
Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.
The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).